Search research articles
Contact Us
Filters
Showing results (161-170 of 166) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 166 results.
Rheumatology (Oxford, England)
|
February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study
Yu Xue, Lingyun Sun, Ning Zhang, et al.
Frontiers in Pharmacology
|
December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
Jinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Jinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology
|
October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
Jinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy
|
March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
Hua Ye, Shengyun Liu, Jian Xu, et al.
Nature Plants
|
July 17, 2019
Musa balbisiana genome reveals subgenome evolution and functional divergence
Zhuo Wang, Hongxia Miao, Juhua Liu, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 166) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 166 results.
Rheumatology (Oxford, England)
|
February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study
Yu Xue, Lingyun Sun, Ning Zhang, et al.
Frontiers in Pharmacology
|
December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
Jinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Jinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology
|
October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
Jinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy
|
March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
Hua Ye, Shengyun Liu, Jian Xu, et al.
Nature Plants
|
July 17, 2019
Musa balbisiana genome reveals subgenome evolution and functional divergence
Zhuo Wang, Hongxia Miao, Juhua Liu, et al.
Page
of 17